About: Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients
Creator	Nguyen, An Crotty, Matthew Akins, Ronda Dominguez, ; Rahmanzadeh, Kristen Slika, Rania Wilson, Marie
Source	MedRxiv
abstract	Background SARS-CoV-2 has drastically affected healthcare globally and causes COVID-19, a disease that is associated with substantial morbidity and mortality. We aim to describe rates and pathogens involved in co-infection or subsequent infections and their impact on clinical outcomes among hospitalized patients with COVID-19. Methods Incidence of and pathogens associated with co-infections, or subsequent infections, were analyzed in a multicenter observational cohort. Clinical outcomes were compared between patients with a bacterial respiratory co-infection (BRC) and those without. A multivariable Cox regression analysis was performed evaluating survival. Results A total of 289 patients were included, 48 (16.6%) had any co-infection and 25 (8.7%) had a BRC. No significant differences in comorbidities were observed between patients with co-infection and those without. Compared to those without, patients with a BRC had significantly higher white blood cell counts, lactate dehydrogenase, C-reactive protein, procalcitonin and interleukin-6 levels. ICU admission (84.0 vs 31.8%), mechanical ventilation (72.0 vs 23.9%) and in-hospital mortality (45.0 vs 9.8%) were more common in patients with BRC compared to those without a co-infection. In Cox proportional hazards regression, following adjustment for age, ICU admission, mechanical ventilation, corticosteroid administration, and pre-existing comorbidities, patients with BRC had an increased risk for in-hospital mortality (adjusted HR, 3.37; 95% CI, 1.39 to 8.16; P = 0.007). Subsequent infections were uncommon, with 21 infections occurring in 16 (5.5%) patients. Conclusions Co-infections are uncommon among hospitalized patients with COVID-19, however, when BRC occurs it is associated with worse clinical outcomes including higher mortality.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1101/2020.05.29.20117176
has license	medrxiv
sha1sum (hex)	ca39903c768f68dfbc6b6c3822e70551e0fc8c30
schema:url	https://doi.org/10.1101/2020.05.29.20117176
resource representing a document's title	Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients
resource representing a document's body	covid:ca39903c768f68dfbc6b6c3822e70551e0fc8c30#body_text
is schema:about of	named entity 'Incidence' named entity 'BRC' named entity 'survival' named entity 'SARS-CoV-2' named entity 'pathogens' named entity 'BRC' named entity 'OBSERVED' named entity 'IN-HOSPITAL MORTALITY' named entity 'THEIR' named entity 'ADJUSTMENT' named entity 'C-REACTIVE PROTEIN' named entity 'INFECTIONS' named entity 'COX PROPORTIONAL HAZARDS REGRESSION' named entity 'SIGNIFICANT' named entity 'TOTAL' named entity 'FOLLOWING' named entity 'PATIENTS' covid:arg/ca39903c768f68dfbc6b6c3822e70551e0fc8c30 named entity 'COVID-19' named entity 'BRC' named entity 'involved' named entity 'multicenter' named entity 'patients' named entity 'patients' named entity 'acute care hospitals' named entity 'empiric antibiotic' named entity 'Cox regression' named entity 'C-reactive protein' named entity 'globally' named entity 'Methods' named entity 'white blood cell counts' named entity 'comorbidities' named entity '95% CI' named entity 'ICU' named entity 'comorbidities' named entity 'co-infection' named entity 'COVID-19' named entity 'pathogens' named entity 'pathogens' named entity 'clinical outcomes' named entity 'multiple comparisons' named entity 'nucleic acid tests' named entity 'critical illness' named entity 'systemic corticosteroids' named entity 'antigen' named entity 'morbidity' named entity 'CC-BY-NC-ND 4.0' named entity 'C. difficile' named entity 'serum' named entity 'medRxiv' named entity 'RT-PCR' named entity 'Sparks, MD' named entity 'RT-PCR' named entity 't-test' named entity 'broad spectrum' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'coronary artery disease' named entity 'viruses' named entity 'COVID-19' named entity 'mechanical ventilation' named entity 'May 30' named entity 'Urine' named entity 'Brea' named entity 'BD Diagnostics' named entity 'bivariate analysis' named entity 'nucleic acid' named entity 'co-infection' named entity 'Lenexa' named entity 'coronavirus' named entity 'nominal data' named entity 'COVID' named entity 'informed consent' named entity 'SARS-CoV-2' named entity 'co-infection' named entity 'chronic obstructive pulmonary disease' named entity 'respiratory infections' named entity 'cirrhosis' named entity 'S. pneumoniae'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software